In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Hoechst AG buys remaining 43.5% of Roussel-Uclaf

Executive Summary

Hoechst AG plans to buy the remaining 43.5% of Roussel-Uclaf that it does not already own, in a transaction valued at 16bn francs, or $3.6bn. Hoechst offered 1530 francs or $291 a share, which is a 12% premium over Roussel's average stock price.
Deal Industry
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Partial Acquisition
    • Payment Includes Cash

Related Companies